A glimmer of hope may be emerging for individuals grappling with ALS, as researchers herald a potential “breakthrough” medication.
Neuvivo, a biopharmaceutical pioneer nestled in the heart of California, is advocating for the approval of a novel treatment aimed at combatting ALS (amyotrophic lateral sclerosis).
ALS is a relentless and progressive neurodegenerative affliction that meticulously dismantles muscle function, ultimately stripping away a patient’s abilities to walk, speak, eat, and even breathe, according to the ALS Association’s findings.
A MOTHER WITH ALS SHARES A HEARTWARMING WEDDING DANCE WITH HER SON IN FLORIDA
This month, Neuvivo took a significant step by submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an infusion treatment known as NP001 (sodium chlorite infusion).
A potential breakthrough drug could offer fresh hope for ALS patients, researchers assert. (iStock)
The FDA has granted NP001 with orphan drug and fast track designations, paving the way for a potential Accelerated Approval and Priority Review, a move that could significantly expedite the approval timeline, as detailed in Neuvivo’s recent press release.
Dr. Matthew W. Davis, the chief medical officer at Neuvivo, shared with Fox News Digital, “If given the green light, NP001 would not only stand as the first immunotherapy specifically for ALS but would also be the inaugural treatment proven to preserve lung function.”
A CRUCIAL NEED
Presently, there are no FDA-sanctioned therapies that not only maintain respiratory function but also extend survival beyond a meager two to three months, as highlighted by the company.
The foremost cause of mortality among ALS sufferers is attributed to a decline in lung function, culminating in respiratory failure.
A MAN PARALYZED BY A DIVING ACCIDENT EXPERIENCES MEDICAL MIRACLE FOLLOWING AI-POWERED BRAIN IMPLANT
Statistics indicate that approximately 30,000 adults in the United States currently battle ALS — a staggering one in every 300 individuals will confront this diagnosis in their lifetime.
Shockingly, the average life expectancy following an ALS diagnosis is a mere 18 months.
Unlike existing therapies that primarily target the nervous system, NP001 aims to manage inflammation within the immune system, offering a novel approach. (iStock)
“Tragically, half of those diagnosed with ALS today may not survive beyond three years,” Dr. Davis lamented.
Dr. Earnest Lee Murray, a board-certified neurologist at Jackson-Madison County General Hospital in Tennessee, corroborated the notion that current treatments for ALS are starkly “limited” in efficacy.
A NOVEL THERAPEUTIC APPROACH
While many existing drugs contend with ALS through the nervous system, NP001, upon receiving approval, would emerge as the first therapy targeting immune system inflammation.
“This treatment would extend to all ALS patients, though our findings indicate that those with marked inflammation may derive considerably greater benefits,” Davis asserted.
“Tragically, half of those diagnosed with ALS today may not survive beyond three years.”
Dr. Murray emphasized the detrimental role of excessive inflammation in exacerbating muscle weakness associated with ALS.
Initial explorations into NP001 yielded no “statistically significant” enhancements; however, a reassessment of previous data focused on specific patient subgroups exhibiting high inflammatory markers.
As ALS progresses, it relentlessly attacks muscle functions, leading to debilitating effects for patients. (iStock)
“The findings suggest that NP001 may decelerate the relentless decline of muscle function, particularly in preserving respiratory capabilities, by specifically targeting immune cells known as macrophages,” Dr. Murray conveyed to Fox News Digital.
CLICK HERE TO ACCESS THE FOX NEWS APP
“Interrupting the activation of macrophages can cascade into effects on other immune cells, potentially shifting the trajectory of ALS,” he added.
In the initial month of treatment, NP001 is administered as a 30-minute infusion, repeated daily over five consecutive days. (iStock)
For the first month, NP001 is delivered via a 30-minute infusion each day for five consecutive days. Following this initial period, patients will receive treatments for three consecutive days each month thereafter, as outlined by Davis.
CLICK HERE TO SUBSCRIBE TO OUR HEALTH NEWSLETTER
In clinical trials, NP001 was found to be “generally well-tolerated,” as reported by Davis.
The most frequently observed side effects included transient pain, redness, and swelling at the infusion site, all of which were classified as “generally mild.”
“The findings suggest that NP001 may decelerate the relentless decline of muscle function.”
Echoing a positive sentiment, Dr. Murray remarked that early studies indicate NP001 is safe and well-tolerated. “With cautious optimism, I trust that as NP001 progresses through the FDA’s clinical trial process, it will exhibit real improvements for ALS patients, offering a sliver of hope to those families facing this heart-wrenching disease,” he expressed.
For a wealth of health-related articles, navigate to www.foxnews.com/health
As the crucial FDA review unfolds, Neuvivo plans to keep patients and caregivers in the loop with timely updates available on its website, according to Davis.
